Compare iShares MSCI Hong Kong ETF (EWH) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: iShares MSCI Hong Kong ETF is far larger — about 10.3× Inovio Pharmaceuticals Inc's market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EWH | INO | |
|---|---|---|
Market Cap | $1.16B | $112.19M |
Volume | 3,176,523 | 3,201,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $2.60 |
52-Week Low | $20.66 | $0.66 |
Typical Hold Time | 61 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $21.72 with a 0.65% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Moving averages signal strong bearish momentum while oscillators remain neutral. Recent institutional selling includes Empowered Funds LLC reducing its position by 70.2% in Q2 2026.
Outlook remains cautious given Hong Kong market volatility and geopolitical risks. The ETF's performance is tied to Chinese tech stocks and regional economic conditions. Near-term resistance at $22 presents a key level for bullish reversal, but continued pressure on Asian markets suggests limited upside potential without significant catalyst.
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
